IRVINE, Calif. — CombiMatrix Corporation (Nasdaq:CBMX) announced today that it has received its Clinical Laboratory Permit from the New York State Department of Health. The permit allows the Company to immediately begin receiving specimens for DNAarray™ Postnatal Developmental Testing. The DNAarray tests are based on aCGH technology, which provides physicians with a comprehensive genomic evaluation for individuals with disorders ranging from autism to mental retardation and birth defects.

“We are excited at the opportunity to provide our genomic services to physicians and patients throughout the state of New York,” said Judd Jessup, President and CEO of CombiMatrix. “With the rigorous quality standards set by the state, we are pleased about receiving New York State approval, which recognizes the quality of our testing that is performed at our genomics laboratory campus,” concluded Mr. Jessup.

The Company now has clinical laboratory licenses from all major states, including California, Florida, Pennsylvania, Maryland and Rhode Island, as well as CLIA and CAP accreditations.

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix Diagnostics (“CMDX”), is a CAP/CLIA certified molecular diagnostics laboratory offering comprehensive profiling of chromosomes and genes for both oncology and pre- and postnatal developmental disorders. CombiMatrix Diagnostics offers a comprehensive and proprietary analysis of tumors at the DNA, or molecular level. CombiMatrix was the first commercial clinical laboratory in the United States to make comprehensive DNA-based genomic analysis of solid tumors, including breast, colon, lung, prostate and brain tumors, available to oncology patients and medical professionals. CombiMatrix also offers pre- and postnatal testing services for the detection of chromosomal and genetic abnormalities beyond what can be identified through traditional technologies.